A new UK startup is developing a unique new method for testing the impact of pharmaceutical drugs on the heart without having to resort to animal testing or early-stage human clinical trials. InoCardia, the company in question, is a spin-out from the University of Coventry. It is currently in the process of validating the model and commercialising the business. It has already attracted funding from Mercia Fund Management, a Venture Capital (VC) fund that has tie-ins with eight West Midlands universities and specialises in sectors such as medical research, disruptive technology, financial technology and e-commerce.
Hey, check out all the engineering jobs. Post your resume today!
